Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Emgality ® (galkanezumab)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The Instructions for Use of Emgality mentions the following
Make sure the pen is locked. Leave the base cap on until you are ready to inject.
When you are ready to inject, twist off the base cap and throw it away in the bin.
Do not put the base cap back on – this could damage the needle.
Do not touch the needle.1
What if the base cap is accidentally removed
The medicine must be injected immediately after the base cap is removed. The base cap should not be removed until ready to inject the dose. Here is why:
If the base cap is removed and the injection is not given immediately, the medicine can dry in the needle pathway. This can cause the needle to clog. If the needle is clogged, the pen will not deliver the dose.
The base cap keeps the needle sterile and protects the patient from an accidental needlestick. The pen should not be stored without the base cap on it because dirt or bacteria can get into the needle.2
If the base cap was removed and it is not time for the injection, the pen should be disposed and a new one should be used.2
What if the pen is unlocked and the teal injection button is pressed before twisting off the base cap
The base cap should not be removed. The pen should be disposed and a new one should be used.1
The instructions for using the pen included with the Package Leaflet, must be followed carefully. The pre-filled pen is for total use only.3
After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate. 3
3. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2019 M02 15